替格瑞洛ChampionPhoenixIII期临床试验结果系列.pptx

Dr. Bhatt – Advisory Board: Medscape Cardiology; Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers; Chair: American Heart Association Get With The Guidelines Science Subcommittee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees); Other: Senior Associate Editor, Journal of Invasive Cardiology; Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda.
This presentation includes off-label and/or investigational uses of drugs, including clopidogrel and cangrelor.
The CHAMPION PHOENIX trial was funded by The Medicines Company.
Disclosures
Antiplatelet Therapy
Antiplatelet therapy is a critical part of contemporary PCI.
In the era of aspirin and unfractionated heparin, intravenous glycoprotein IIb/IIIa inhibition significantly reduced important periprocedural ischemic events, but significantly increased bleeding.
ADP receptor antagonism with oral agents was also shown to reduce ischemic events in PCI and especially ACS.
However, available oral agents are limited by their relatively long duration of action and bioavailability, which might be a liability:
if given prior to coronary angiography and urgent or emergent CABG is deemed necessary,
in situations where absorption may be problematic, such as with rapid times to PCI,
in patients who are intubated, nauseated, with STEMI, or shock.
Harrington RA, et al. PURSUIT. NEJM 1998
Desai N and Bhatt DL. Periprocedural Antiplatelet Therapy. JACC Intervention 2010
Cangrelor
Cangrelor is an intravenous ADP receptor antagonist that is rapidly acting, potent, and reversible, with return of normal platelet function within an hour.
Cangrelor was studied previously in two